The Pharma & Healthcare industry is of vital importance for human and economic development, providing a wide range of goods and services relevant to the promotion of health at all stages in the healthcare process – from prevention and treatment to rehabilitation and palliative care. It is one of the fastest-growing industries, supported by profound demographic changes, the rising incidence of non-communicable diseases, and surging per capita health spending in both developed and emerging markets. The industry is also one of the major innovators, with increasing expenditures on development of new molecules, biotechnology and adoption of new technologies that provide advanced healthcare and ensure the longevity of the population.
The Pharma & Healthcare industry comprises the manufacture of pharmaceuticals for human and veterinary use, medical equipment and related supplies. It also includes providers of ambulatory health services, medical and diagnostic laboratories, hospitals, and nursing and residential care facilities.
Indonesia has one of the fastest-growing pharmaceuticals and healthcare sectors in the ASEAN region, in large part due to the government’s active role in encouraging development. Still, Indonesia’s healthcare services provision is ...View more details
In the past two decades, Latin America has embraced a universal health strategy, based on the principles of equity, solidarity and collective action. This strategy required steadily growing public expenditure on health in order to guarantee universal ...View more details
Due to a growing and ageing population, and an increasing incidence of non-communicable diseases, Brazil became the seventh largest pharmaceutical market in the world in 2018. During the year, retail drug sales, based on pharmacy purchase price (PPP) ...View more details
Mexico is the second largest pharmaceutical market in Latin America, behind only Brazil, with retail drug sales of USD 10.2bn in 2018. The country also features a growing and ageing population, multiple but underfunded state-run health insurance ...View more details
In Q3 2019 China’s healthcare sector continued to expand, stimulated by further structural reforms. The period saw increased government spending on healthcare, with expenditure on health and family planning growing by 12.1% y/y to RMB 369.3bn. ...View more details
Although quite different in terms of political and economic systems, the Emerging Europe countries share certain similarities when it comes to their demographic situation and health profile. With the exception of Turkey, whose average birth rate is ...View more details
In a Latin American context, Chile is not a particularly large pharmaceutical and healthcare market, since its population is relatively small and healthy in terms of the incidence of communicable diseases. However, the country’s changing ...View more details
In 2018, Argentina was the third largest pharmaceutical market in Latin America with retail drug sales of USD 4.9bn. The country has a large and ageing population, a relatively developed public health system, and a small but consolidated private ...View more details
Malaysia has one of the most developed pharmaceuticals and healthcare sectors in the ASEAN region. The country operates a dual public-private healthcare system in which the government, under the Ministry of Health (“MoH”), both regulates ...View more details
China’s healthcare sector kept growing over the second quarter of 2019. The period was characterised by increased government spending on healthcare, with the amount dedicated to health and family planning rising by 5.9% y/y to RMB 534.5bn in Q2 ...View more details